TP53 in AML and MDS: The new (old) kid on the block.

Humans Myelodysplastic Syndromes / diagnosis Leukemia, Myeloid, Acute / diagnosis Mutation Myeloproliferative Disorders Prognosis Tumor Suppressor Protein p53 / genetics
Acute myeloid leukemia International consensus classification Myelodysplastic syndrome TP53 World Health Organization

Journal

Blood reviews
ISSN: 1532-1681
Titre abrégé: Blood Rev
Pays: England
ID NLM: 8708558

Informations de publication

Date de publication:
07 2023
Historique:
received: 25 12 2022
revised: 07 02 2023
accepted: 08 02 2023
medline: 3 7 2023
pubmed: 26 2 2023
entrez: 25 2 2023
Statut: ppublish

Résumé

MDS and AML are clonal hematopoietic stem cell disorders of increasing incidence, having a variable prognosis based, among others, on co-occurring molecular abnormalities. TP53 mutations are frequently detected in these myeloid neoplasms and portend a poor prognosis with known therapeutic resistance. This article provides a timely review of the complexity of TP53 alterations, providing updates in diagnosis and prognosis based on new 2022 International Consensus Classification (ICC) and World Health Organization (WHO) guidelines. The article addresses optimal testing strategies and reviews current and arising therapeutic approaches. While the treatment landscape for this molecular subgroup is under active development, further exploration is needed to optimize the care of this group of patients with unmet needs.

Identifiants

DOI: 10.1016/j.blre.2023.101055 PMID: 36841672
pubmed: 36841672
pii: S0268-960X(23)00016-4
doi: 10.1016/j.blre.2023.101055
pii:
doi:

Substances chimiques

TP53 protein, human 0
Tumor Suppressor Protein p53 0

Banques de données

ClinicalTrials.gov
['NCT04755244', 'NCT02663518']

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

101055

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Auteurs

Jennifer A Marks (JA)

Department of Medicine, Division of Hematology and Oncology, Georgetown University, 3800 Reservoir Road NW, Washington, D.C. 20007, USA. Electronic address: jennifer.a.marks@medstar.net.

Xin Wang (X)

Department of Medicine, Division of Hematology and Oncology, Georgetown University, 3800 Reservoir Road NW, Washington, D.C. 20007, USA; Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, 12 South Pavilion, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA. Electronic address: xin.wang2@pennmedicine.upenn.edu.

Elena M Fenu (EM)

Department of Pathology and Laboratory Medicine, Division of Hematopathology, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA. Electronic address: elena.fenu@pennmedicine.upenn.edu.

Adam Bagg (A)

Department of Pathology and Laboratory Medicine, Division of Hematopathology, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA. Electronic address: adambagg@pennmedicine.upenn.edu.

Catherine Lai (C)

Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, 12 South Pavilion, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA. Electronic address: catherine.lai@pennmedicine.upenn.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › TP53 in AML and MDS: The new (old) kid on the block.
questionsmedicales.fr › Hémopathies et maladies lymphatiques › Hémopathies › Maladies de la moelle osseuse › Syndromes myélodysplasiques › TP53 in AML and MDS: The new (old) kid on the block.
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › Leucémie myéloïde › Leucémie aigüe myéloïde › TP53 in AML and MDS: The new (old) kid on the block.
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › TP53 in AML and MDS: The new (old) kid on the block.
questionsmedicales.fr › Hémopathies et maladies lymphatiques › Hémopathies › Maladies de la moelle osseuse › Syndromes myéloprolifératifs › TP53 in AML and MDS: The new (old) kid on the block.
questionsmedicales.fr › Diagnostic › Pronostic › TP53 in AML and MDS: The new (old) kid on the block.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Phosphoprotéines › Protéine p53 suppresseur de tumeur › TP53 in AML and MDS: The new (old) kid on the block.